Neuropediatrics
DOI: 10.1055/s-0044-1786796
Original Article

Levetiracetam Dosing Based on Glasgow Coma Scale Scores in Pediatric Traumatic Brain Injury Patients

Victoria Miklus
1   Department of Pharmacy, Penn State College of Medicine, Penn State Health Children's Hospital, Hershey, Pennsylvania, United States
,
Lindsay Trout
1   Department of Pharmacy, Penn State College of Medicine, Penn State Health Children's Hospital, Hershey, Pennsylvania, United States
,
Katelyn Even
2   Department of Pediatrics, Penn State College of Medicine, Penn State Health Children's Hospital, Hershey, Pennsylvania, United States
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Introduction Severe traumatic brain injury (TBI) increases the risk of early posttraumatic seizures (EPTS). Guidelines suggest the use of prophylactic antiseizure agents, including levetiracetam. This study aims to evaluate the feasibility of using levetiracetam dosing based on Glasgow Comas Scale (GCS) scores with higher doses used for more severe TBI.

Methods Patients 6 months to 18 years old admitted to Penn State Hershey Children's Hospital (PSHCH) with a TBI who received levetiracetam for EPTS prophylaxis with at least one documented GCS score were included. Patients were divided into two cohorts: before and after implementation of the pediatric TBI Cerner PowerPlan at PSHCH which standardized levetiracetam dosing based on GCS scores. Primary outcome was appropriate dosing of levetiracetam based on GCS. Secondary outcomes included seizure occurrence and adverse effects.

Results Eighty-five patients were included: 42 in the pre-PowerPlan group and 43 in the post-PowerPlan group. Overall, 46 (54%) patients received the appropriate levetiracetam dose based on GCS (pre-PowerPlan, n = 19 [45%] vs. post-PowerPlan n = 27 [63%], p = 0.104). Sixty-four percent of severe TBI patients received appropriate levetiracetam dosing after implantation of the PowerPlan compared with 28% prior to the PowerPlan (p = 0.039). Three patients in each group experienced a seizure while on levetiracetam. Two patients experienced agitation and somnolence attributed to levetiracetam.

Conclusion Levetiracetam dosing based on GCS scores in pediatric TBI patients is a novel approach, and dosing accuracy may be increased with use of a PowerPlan. Additional large-scale studies are needed to evaluate efficacy and safety of this approach prior to widespread implementation.

Keywords

seizures - levetiracetam - traumatic brain injury - critical care


Publication History

Received: 31 January 2024

Accepted: 15 April 2024

Article published online:
13 May 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Carney N, Totten AM, Ullman JS. et al. Guidelines for the management of severe traumatic brain injury. Neurosurgery 2017; 80: 6-15
    CrossrefPubMedGoogle Scholar
  • 2 GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Lobal, regional and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18 (01) 56-87
    CrossrefPubMedGoogle Scholar
  • 3 Liesemer K, Bratton SL, Zebrack CM, Brockmeyer D, Statler KD. Early post-traumatic seizures in moderate to severe pediatric traumatic brain injury: rates, risk factors, and clinical features. J Neurotrauma 2011; 28 (05) 755-762
    CrossrefPubMedGoogle Scholar
  • 4 Shin T, Oh K, Cha BH. The risk factors and clinical features of posttraumatic seizure in preschool-aged children. Ann Neurol 2019; 27: 22-28
    CrossrefPubMedGoogle Scholar
  • 5 Chung MG, O'Brien NF. Prevalence of early posttraumatic seizures in children with moderate to severe traumatic brain injury despite levetiracetam prophylaxis. Pediatr Crit Care Med 2016; 17 (02) 150-156
    CrossrefPubMedGoogle Scholar
  • 6 Thapa A, Chandra SP, Sinha S, Sreenivas V, Sharma BS, Tripathi M. Post-traumatic seizures-a prospective study from a tertiary level trauma center in a developing country. Seizure 2010; 19 (04) 211-216
    CrossrefPubMedGoogle Scholar
  • 7 Kochanek PM, Tasker RC, Carney N. et al. Guidelines for the management of pediatric severe traumatic brain injury, Third Edition: Update of the Brain Trauma Foundation Guidelines. Pediatr Crit Care Med 2019; 20: S1-S82
    CrossrefPubMedGoogle Scholar
  • 8 Haque KD, Grinspan ZM, Mauer E, Nellis ME. Early use of antiseizure medication in mechanically-ventilated traumatic brain injury patient cases: a retrospective pediatric health information database study. Pediatr Crit Care Med 2021; 22 (01) 90-100
    CrossrefPubMedGoogle Scholar
  • 9 Surtees TL, Kumar I, Garton HJL. et al. Levetiracetam prophylaxis for children admitted for traumatic injury. Pediatr Neurol 2022; 126: 114-119
    CrossrefPubMedGoogle Scholar
  • 10 Ramael S, Daoust A, Otoul C. et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006; 47 (07) 1128-1135
    CrossrefPubMedGoogle Scholar
  • 11 Jones KE, Puccio AM, Harshman KJ. et al. Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurg Focus 2008; 25 (04) E3
    CrossrefPubMedGoogle Scholar
  • 12 Ohman K, Kram B, Schultheis J. et al. Evaluation of levetiracetam dosing strategies for seizure prophylaxis following traumatic brain injury. Neurocrit Care 2023; 38 (02) 345-355
    CrossrefPubMedGoogle Scholar
  • 13 Pearl PL, McCarter R, McGavin CL. et al. Results of phase II levetiracetam trial following acute head injury in children at risk for posttraumatic epilepsy. Epilepsia 2013; 54 (09) e135-e137
    CrossrefPubMedGoogle Scholar
  • 14 Kolf MJ, McPherson CC, Kniska KS, Luecke CM, Lahart MA, Pineda JA. Early post-traumatic seizure occurrence in pediatric patients receiving levetiracetam prophylaxis with severe traumatic brain injury. J Pediatr Pharmacol Ther 2020; 25 (03) 241-245
    PubMedGoogle Scholar
  • 15 Bowman SM, Bird TM, Aitken ME, Tilford JM. Trends in hospitalizations associated with pediatric traumatic brain injuries. Pediatrics 2008; 122 (05) 988-993
    CrossrefPubMedGoogle Scholar
  • 16 Ducrocq SC, Meyer PG, Orliaguet GA. et al. Epidemiology and early predictive factors of mortality and outcome in children with traumatic severe brain injury: experience of a French pediatric trauma center. Pediatr Crit Care Med 2006; 7 (05) 461-467
    CrossrefPubMedGoogle Scholar
  • 17 Parks SE, Annest JL, Hill HA. et al. Pediatric abusive head trauma: recommended definitions for public health surveillance and research. Centers for Disease Control and Prevention. April 2012 . Accessed November 27, 2023 at: https://stacks.cdc.gov/view/cdc/26243
    PubMedGoogle Scholar
  • 18 Oh A, Olson LD, Chern JJ, Kim H. Clinical characteristics and nonconvulsive seizures in young children with abusive head trauma. J Child Neurol 2019; 34 (12) 713-719
    CrossrefPubMedGoogle Scholar
  • 19 Laing J, Gabbe B, Chen Z, Perucca P, Kwan P, O'Brien TJ. Risk factors and prognosis of early posttraumatic seizures in moderate to severe traumatic brain injury. JAMA Neurol 2022; 79 (04) 334-341
    CrossrefPubMedGoogle Scholar
  • 20 Rumalla K, Smith KA, Letchuman V, Gandham M, Kombathula R, Arnold PM. Nationwide incidence and risk factors for posttraumatic seizures in children with traumatic brain injury. J Neurosurg Pediatr 2018; 22 (06) 684-693
    CrossrefPubMedGoogle Scholar
  • 21 Verrotti A, Prezioso G, Di Sabatino F, Franco V, Chiarelli F, Zaccara G. The adverse event profile of levetiracetam: a meta-analysis on children and adults. Seizure 2015; 31: 49-55
    CrossrefPubMedGoogle Scholar
  • 22 Depositario-Cabacar DT, Peters JM, Pong AW. et al. High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy. Epilepsia 2010; 51 (07) 1319-1322
    CrossrefPubMedGoogle Scholar
  • 23 Lamouret V, Kurth C, Intravooth T, Steinhoff BJ. Is the anticonvulsant activity of levetiracetam dose-dependent?. Seizure 2020; 83: 197-202
    CrossrefPubMedGoogle Scholar
  • 24 Hirsch LJ, Arif H, Buchsbaum R. et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia 2007; 48 (07) 1351-1359
    CrossrefPubMedGoogle Scholar
  • 25 Tekgül H, Gencpinar P, Çavuşoğlu D, Dündar NO. The efficacy, tolerability and safety of levetiracetam therapy in a pediatric population. Seizure 2016; 36: 16-21
    CrossrefPubMedGoogle Scholar
  • 26 Coronado VG, Xu L, Basavaraju SV. et al; Centers for Disease Control and Prevention (CDC). Surveillance for traumatic brain injury-related deaths–United States, 1997-2007. MMWR Surveill Summ 2011; 60 (05) 1-32
    PubMedGoogle Scholar